SCHEMBL6749423

SCHEMBL6749423

Oc1cccc2c1CCC=C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.41
BAD Q92934 1/20 0.41
DRD2 P14416 3/20 0.34
DRD3 P35462 2/20 0.34
PARP1 P09874 1/20 0.34
ALDH1A1 P00352 2/20 0.33
EGFR P00533 2/20 0.33
CA2 P00918 2/20 0.33
LMNA P02545 2/20 0.33
FYN P06241 2/20 0.33
MMP9 P14780 2/20 0.33
HPGD P15428 2/20 0.33
ALOX15 P16050 2/20 0.33
RECQL P46063 2/20 0.33
HSD17B10 Q99714 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
ADAMTS4 O75173 1/20 0.33
CA1 P00915 1/20 0.33
MMP2 P08253 1/20 0.33
MMP8 P22894 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27486701 0.83 ALDH1A1 (0.35) BCL2L1BADDRD2DRD3PARP1
SCHEMBL276579 0.78 BCL2L1 (0.39) BCL2L1BADDRD2DRD3PARP1
SCHEMBL28149914 0.78 BCL2L1 (0.43) BCL2L1BADDRD2DRD3PARP1
SCHEMBL27664477 0.77 BCL2L1 (0.38) BCL2L1BADDRD2DRD3PARP1
SCHEMBL14714269 0.75
SCHEMBL31170847 0.75 PARP10 (0.34)
SCHEMBL31170737 0.75 ADRA2A (0.36) LMNA
SCHEMBL19692682 0.75 PARP1 (0.34) PARP1ALDH1A1CA2CA1
SCHEMBL12320946 0.75
SCHEMBL7650577 0.75 CD44 (0.36) PARP1ALDH1A1LMNAHPGDALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340539-A1 COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF GENEORA PHARMA (SHIJIAZHUANG) CO., LTD. (CN) 2022-10-27 US claimed
EP-4039678-A1 COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF Shandong Luye Pharmaceutical Co., Ltd. (CN) 2022-08-10 EP claimed
CN-114423746-A Compound and preparation method and application thereof 山东绿叶制药有限公司 2022-04-29 CN claimed
WO-2021063347-A1 COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF 山东绿叶制药有限公司 2021-04-08 WO claimed
WO-2013083582-A1 ANTIMICROBIAL COMPOSITION UNILEVER N.V. (NL) 2013-06-13 WO claimed
EP-4649941-A1 METHOD FOR PREPARING STERILE IN-SITU GEL ON BASIS OF SOLVENT REMOVAL TECHNIQUE AND PRODUCT THEREOF Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. (CN) 2025-11-19 EP disclosed
EP-4628076-A1 ROTIGOTINE-CONTAINING PATCH AND METHOD FOR IMPROVING STABILITY OF ROTIGOTINE Hisamitsu Pharmaceutical Co., Inc. (JP) 2025-10-08 EP disclosed
US-20250161265-A1 ROTIGOTINE-CONTAINING ADHESIVE PATCH HISAMITSU PHARMACEUTICAL CO., INC. (JP) 2025-05-22 US disclosed
EP-4483873-A1 ROTIGOTINE-CONTAINING ADHESIVE PATCH Hisamitsu Pharmaceutical Co., Inc. (JP) 2025-01-01 EP disclosed
US-20240415765-A1 CONTINUOUS DELIVERY PREPARATION CAPABLE OF BEING STABLY RELEASED AND PREPARATION METHOD THEREFOR SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) 2024-12-19 US disclosed
EP-4454636-A1 CONTINUOUS DELIVERY PREPARATION CAPABLE OF BEING STABLY RELEASED AND PREPARATION METHOD THEREFOR Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. (CN) 2024-10-30 EP disclosed
CN-118843462-A Rotigotine-containing patch 久光制药株式会社 2024-10-25 CN disclosed
CN-1402633-A Transdermal therapeutic system with improved stability and method for the production thereof LOHMANN THERAPIE SYST LTS (DE) 2003-03-12 CN disclosed
WO-2003015715-A2 TETRAHYDROQUINOLINE DERIVATIVES AS ANTITHROMBOTIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-02-27 WO disclosed
EP-0157436-B1 PERFUME COMPOSITIONS AND PERFUMED ARTICLES CONTAINING DIHYDRO- AND/OR TETRAHYDRO-NAPHTOLS AS FRAGRANCE MATERIAL NAARDEN INTERNATIONAL N.V. (NL) 1990-01-03 EP disclosed
US-4643844-A LEATHER ODOR 501 Naarden International N.V. (NL) 1987-02-17 US disclosed
EP-0157436-A1 Perfume compositions and perfumed articles containing dihydro- and/or tetrahydro-naphtols as fragrance material NAARDEN INTERNATIONAL N.V. (NL) 1985-10-09 EP disclosed
US-4435397-A ADRENERGIC BLOCKING AGENTS, 4-(3-ARYLOXY-2-HYDROXYPROPYL) SUBSTITUTED NIPPON SHINYAKU CO., LTD. (JP) 1984-03-06 US disclosed
US-4265911-A Propionamidoxime derivatives SYNTHELABO (FR) 1981-05-05 US disclosed
US-3943149-A HYPOCHOLESTEREMIC, ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220340539-A1 COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF FURIN, VIP, SORD BCL2L1 4263/4885BAD 1736/4885DRD2 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.